We read with interest the article by Georgiadou et al. 1 on the impact of prior invasive mould infections in leukaemia patients undergoing allo-SCT in the era of triazole-based secondary prophylaxis. They reported a rate of 14% breakthrough infections and no invasive mould infection-related mortality in their retrospective analysis of 29 patients. These results compare favourably with the few previous reports on the outcome of allo-SCT in patients with a history of invasive fungal infection (IFI).
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We report here similarly favourable results on the use of secondary antifungal prophylaxis (SAP) and conclude that prior IFI should not preclude allo-SCT if otherwise indicated.
We retrospectively collected data on patients with pretransplant IFI treated at Turku University Hospital between January 2010 and September 2012 and identified 11 patients with a history of IFI among the 100 recipients of allogeneic SCT. The median age was 47 (18-66) years. The underlying disease was AML (n ¼ 6), ALL (2), acute undifferentiated leukemia (AUL) (1), myelodysplastic syndrome (MDS) (1) and severe aplastic anemia (SAA) (1), and disease status at transplant was CR1 (3), CR2 (4), PR (1) and refractory disease (3). Conditioning regimen was myeloablative in three patients and reduced-intensity conditioning or treosulfan-based in others. Four patients received sequential conditioning with FLAMSA induction. The IFI diagnosis according to the EORTC/MSG criteria 4 was proven, probable and possible in 3, 3 and 5 patients, respectively. The site of infection was lung (7), liver (2) and both (2), respectively. Voriconaxole was the most often used drug in the primary treatment. The median duration of antifungal treatment before SCT was 8 months (5-112 weeks) and the IFI status at transplantation was CR (3) and PR (8).
Patients in PR had some residual radiological abnormalities high resolution computed tomography (HRCT) of the lung or liver magnetic resonance imaging) but no symptoms related to infection. All patients received Ambisome (Amb) as SAP during the peritransplant period. After engraftment eight patients received Voriconazole (alone n ¼ 5; in combination/sequentially with Amb n ¼ 3), two patients received other azoles and one patient died before the outpatient phase. The median duration of SAP was 18 weeks (6-66 weeks). Among the seven patients alive, five patients are still receiving antifungal therapy. With a median follow-up time of 7 (1-24) months, there were no IFI-related deaths and only two possible IFI reactivations, one occurring after cessation of SAP after 49 weeks of therapy. Summary on the individual patients is presented in Table 1 .
The data by Georgiadou et al. as well as ours support the feasibility of allo-SCT in patients with prior IFI. However, there were also some differences between the findings of Georgiadou et al. 1 and ours, some of which may reflect the lack of evidencebased recommendation on SAP. The choice of antifungal agent should, of course, be based on the sensitivity of the causative fungus. This may not always be achievable despite rigorous diagnostic efforts (brochoalveolar lavage, fine-needle biopsy), as evidenced by the low number of proven IFI cases in our analysis. Most of our patients were treated with voriconazole only, whereas most patients reported by Georgiadou received combination therapy. The median length of fungal treatment prior to transplantation also differed significantly (8 months versus 84 days). The longer treatments in our study may be explained by the significant proportion of patients diagnosed with IFI during their first-line treatment but receiving transplant in CR2. Despite longer treatments only 27% of our patients presented no signs of fungal infection at the time of transplantation in contrast to 59% of patients in the study by Georgiadou. In both studies almost all patients received second-generation triazole for SAP with successful outcome. In our patients the secondary prophylaxis was continued for months after transplantation and there was only one suspected reactivation after cessation of prophylaxis. The median duration of SAP was not reported by Georgiadou et al. Determination of appropriate time to discontinue prophylaxis is one of the many areas where more data is needed. We agree with Georgiadou et al. 1 in that prior IFI may no longer be considered a contraindication for allo-SCT. However, new data are needed to guide the use of SAP and thereby also improve the cost-effectiveness of treatment.
